Coverage
Filings
| Filing | Date |
|---|---|
| GSK announces intention to sell shares in Haleon | 16 May 2024 |
| Director/PDMR Shareholding | 14 May 2024 |
| Block listing Interim Review | 13 May 2024 |
| Board Committee Change | 8 May 2024 |
| Result of AGM | 8 May 2024 |
| Director/PDMR Shareholding | 3 May 2024 |
| 1st Quarter Results | 1 May 2024 |
| Total Voting Rights | 1 May 2024 |
| US FDA accepts new indication filing for Jemperli |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 24 Apr 2024 |
| Director/PDMR Shareholding | 19 Apr 2024 |
| Results from long-term data relating to Shingrix | 17 Apr 2024 |
| GSK announces additional EAGLE-1 results | 17 Apr 2024 |